1. Data on file. Neuronetics, Inc.
  2. O’Reardon JP, et al. (2007). Efficacy and Safety of Transcranial Magnetic Stimulation in the Acute Treatment of Major Depression: A Multisite Randomized Controlled Trial. Biol Psychiatry, 62(11):1208-1216.
  3. George MS, et al. (2010). Daily Left Prefrontal Transcranial Magnetic Stimulation Therapy for Major Depressive Disorder: A Sham-Controlled Randomized Trial. Arch Gen Psychiatry, 67(5):507-516.
  4. United States Census Bureau.
  5. Kessler, RC et al. (2005). Arch Gen Psychiatry, 62(6):593-602.
  6. Gaynes BN, et al. (2008). Cleveland Clinic Journal of Medicine, 75(1):57-66.
  7. World Health Organization. Depression Fact Sheet.
  8. National Institute of Mental Health. US Department of Health and Human Services. Depression.
  9. Per STAR*D patients that have failed one or more antidepressant trial of adequate dose and duration.
  10. Trivedi MH, et al. (2006). Evaluation of Outcomes with Citalopram for Depression Using Measurement-Based Care in STAR*D Implications for Clinical Practice. Am J Psychiatry, 163(1):28-40.
  11. Rush AJ, et al. (2006). Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report. Am J Psychiatry, 163:1905–1917.
  12. Fava M, et al. (2006). A Comparison of Mirtazapine and Nortriptyline Following Two Consecutive Failed Medication Treatments for Depressed Outpatients: A Star*D Report. Am J Psychiatry, 163(7):1161-1172.
  13. McGrath PJ, et al. (2006). Tranylcypromine Versus Venlafaxine Plus Mirtazapine Following Three Failed Antidepressant Medication Trials for Depression: A STAR*D Report. Am J Psychiatry, 163(9):1531-1541.
  14. American Psychiatric Association (2010). (eds: Gelenberg, AJ, Freeman, MP, Markowitz, JC, Rosenbaum, JF, Thase, ME, Trivedi, MH, Van Rhoads, RS). Practice Guidelines for the Treatment of Patients with Major Depressive Disorder, 3rd Edition.
  15. McDonald WM, et al. (2011). Improving the Antidepressant Efficacy of Transcranial Magnetic Stimulation: Maximizing the Number of Stimulations and Treatment Locations in Treatment-Resistant Depression. Depress Anxiety, 28:973-980.
  16. Janicak PG, et al. (2008). Transcranial Magnetic Stimulation in the Treatment of Major Depressive Disorder: A Comprehensive Summary of Safety Experience from Acute Exposure, Extended Exposure, and During Reintroduction Treatment. J Clin Psychiatry, 69(2):222-232.
  17. Liston C, et al. (2014). Default Mode Network Mechanisms of Transcranial Magnetic Stimulation in Depression. Biol Psychiatry, 76(7): 517–526.
  18. Deng ZD, et al. (2013). Electric Field Depth-Focality Tradeoff in Transcranial Magnetic Stimulation: Stimulation Comparison of 50 Coil Designs. Brain Stimuli, 6(1):1-13.
  19. Dunner DL, et al. (2014). A Multisite, Naturalistic, Observational Study of Transcranial Magnetic Stimulation (TMS) for Patients with Pharmacoresistant Major Depression: Durability of Benefit Over a One-Year Follow-Up Period. J Clin Psych, 75(12):1394-1401.
  20. Sackeim, HA, et al. (2020). Clinical Outcomes in a Large Registry of Patients with Major Depressive Disorder Treated with Transcranial Magnetic Stimulation. J Affective Disorders, 277(12):65-74.
  21. Carpenter, LL, et al. (2021). Comparison of Clinical Outcomes with Two Transcranial Magnetic Stimulation Treatment Protocols for Major Depressive Disorder. Brain Stim, 14(1): 173-180.
  22. Post A, et al. (2001). J Psychiatric Research, 35:193-215 6.
  23. Carpenter LL, et al. (2012). Transcranial Magnetic Stimulation (TMS) for Major Depression: A Multisite, Naturalistic, Observational Study of Acute Treatment Outcomes in Clinical Practice. Depress Anxiety, 29(7):587-596.